Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Link to SEPIO compliant JSON-LD document

Variant: NM_001079804.3:c.2456G>C

CA401325305

Gene: GAA

Condition: glycogen storage disease II

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: b9e5a45b-ca59-4eae-888f-d21b7f925693

Approved on: 2022-06-30

Published on: 2022-06-30

HGVS expressions

NM_001079804.3:c.2456G>C

NC_000017.11:g.80117724G>C

CM000679.2:g.80117724G>C

NC_000017.10:g.78091523G>C

CM000679.1:g.78091523G>C

NC_000017.9:g.75706118G>C

NG_009822.1:g.21169G>C

ENST00000302262.8:c.2456G>C

ENST00000302262.7:c.2456G>C

ENST00000390015.7:c.2456G>C

ENST00000573556.1:n.409G>C

NM_000152.3:c.2456G>C

NM_001079803.1:c.2456G>C

NM_001079804.1:c.2456G>C

NM_000152.4:c.2456G>C

NM_001079803.2:c.2456G>C

NM_001079804.2:c.2456G>C

NM_000152.5:c.2456G>C

NM_001079803.3:c.2456G>C

Likely Pathogenic

PP3 PM5_Supporting PP4_Moderate PM2_Supporting PM3 PS3_Moderate

Evidence Links 0

Expert Panel

Lysosomal Diseases VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Lysosomal Diseases VCEP

The NM_000152.5(GAA):c.2456G>C variant in GAA is a missense variant predicted to cause substitution of arginine by proline at amino acid 819 (p.Arg819Pro). This variant has been detected in at least 6 individuals with Pompe disease (PMID: 22644586, 22252923, 30214072) with deficient GAA activity. Of those individuals, one was compound heterozygous for the variant and a pathogenic variant and one was homozygous for the variant (PMID: 30214072, internal lab data), meeting PP4_Moderate and PM3. It is absent in gnomAD, meeting PM2. Functional assays support a deleterious effect of this variant, when expressed in COS cells, this variant was classified as Class B ("potentially less severe") by Kroos et al, 2012 (PMID:22644586). This includes 0.4% GAA activity in cells and 2.0% in medium, and evidence of abnormal synthesis and processing on Western blot. This meets the ClinGen LSD VCEP specifications for PS3_Moderate. Computational evidence also supports a deleterious effect; REVEL score = 0.926 which is higher than the LSD VCEP threshold for PP3 (>0.7) and therefore meets this criterion. Another missense variant [c.2455C>T, p.Arg819Trp] [ClinVar Variation ID:456402] in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen LSD VCEP (PM5_Supporting). There is no Clinvar entry for this variant. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. ACMG/AMP criteria met, based on the specification of the ClinGen LSD VCEP: PP4_Moderate, PM3, PS3_Moderate, PP3, PM2_Supporting, and PM5_Supporting.

PP3

REVEL score = 0.926 which is higher than the LSD VCEP threshold for PP3 (>0.7) and therefore meets this criterion.

PM5_Supporting

Another missense variant [c.2455C>T, p.Arg819Trp] [ClinVar Variation ID:456402] in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen LSD VCEP (PM5_Supporting).

PP4_Moderate

The variant was seen in patients (PMID: 22644586, 22252923, 30214072) with deficient GAA activity but results were not provided and reported to be on enzyme replacement therapy (PMID: 30214072). This meets the criteria for PP4_Moderate

PM2_Supporting

This variant is absent in gnomAD, meeting PM2_Supporting.

PM3

This variant has been detected in at least 6 individuals with Pompe disease (PMID: 22644586, 22252923, 30214072). Of those individuals, one was compound heterozygous for the variant and a pathogenic variant and two were homozygous for the variant (PMID: 30214072, internal lab data). 1.5 point awarded for PM3

PS3_Moderate

When expressed in COS cells, this variant was classified as Class B ("potentially less severe") by Kroos et al, 2012 (PMID:22644586). This includes 0.4% GAA activity in cells and 2.0% in medium, and evidence of abnormal synthesis and processing on Western blot. This meets the ClinGen LSD VCEP specifications for PS3_Moderate.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.